145 search results for: Clinical Management
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE).
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a Symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE). This event is neither sponsored by nor endorsed by ACG.
ADVENT On Air | Eosinophilic Esophagitis: Steering Toward Success
Learn from Drs. Dellon and Wechsler as they discuss best practices in EoE, including highlights from EoE guidelines in the US and EU.
How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz
Join Dr. Miguel Lanz as he explains, in Spanish, the clinical utility of FeNO as a biomarker in severe asthma.
Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind
Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
Emerging Data on Advanced Systemic Treatments for Children With AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga reviewing the systemic treatment landscape for children under 12 years of age with AD in the EU. Dr. Baselga also discusses the latest clinical data on the use of baricitinib in pediatric patients aged 2 to 17 years, and both clinical and real-world data on the efficacy and safety of dupilumab in pediatric patients with AD aged as young as 6 months.
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
This video presentation of the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga, Dr. Amy Paller, and Prof. Lisa Weibel. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating children with AD early in the disease course, and the emerging clinical and real-world data on the use of advanced systemic treatments for children with AD.
World Anosmia Day 2026
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
Can Early Intervention Shape the Course of Atopic Dermatitis?
Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
